![Liquid biopsies are possible because tumours shed bits of themselves into the bloodstream. Image by Carl Dupont via Shutterstock Cancer tumour imaging. Image by Carl Dupont via Shutterstock](/sites/default/files/styles/project_teaser_image/public/uploads/Newsroom%20images/Cancer%20tumour%20imaging.%20Image%20by%20Carl%20Dupont%20via%20Shutterstock.jpg?itok=6HOaqfW4)
The European Liquid Biopsy Society, an offshoot of the IMI project CANCER-ID, is pushing the science on liquid biopsies closer to clinical reality
The European Liquid Biopsy Society, an offshoot of the IMI project CANCER-ID, is pushing the science on liquid biopsies closer to clinical reality
The HARMONY Alliance is using advanced data analysis methods based on artificial intelligence and machine learning to answer questions about haematological malignancies.
IMMUCAN researchers are using extensive imaging data and statistical analysis to produce detailed descriptions of tumours to figure out which regions should be investigated further...
IHI took part in the European Cancer Meeting 2022 of the French National Cancer Institute which was held in Paris, France, on 3 to 4 February 2022. It took place at the French, Economic, Social and...
IHI seeks an ‘outstanding and dynamic professional’ with top leadership, scientific and people skills to take on the role of Executive Director of the public-private partnership...
The European Lead Factory has helped identify two drug candidates for cancer treatment that have now progressed to clinical testing.
The IHI Governing Board has formally approved the Strategic Research and Innovation Agenda (SRIA), which will guide IHI’s scientific priorities in the years to come.
The Innovative Health Initiative (IHI) is looking for people who want to represent the scientific and wider healthcare communities in its new Science and Innovation Panel (SIP)...
HARMONY’s prototype may offer a more precise way for doctors to predict who should undergo the invasive and risky treatment.